Lamictal in the Treatment of Post-Herpetic Neuralgia
Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study
Sponsor: George Washington University
Terminated
enrollment difficult due to inclusion/exclusion criteria/protocol requirements
This PHASE2/PHASE3 trial investigates Neuralgia, Postherpetic and is currently terminated or withdrawn. George Washington University leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Feb 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- George Washington University
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .